Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 04, 2019 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Announces $12.5 Million Debt Financing With Bridge Bank

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
December 20, 2018 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Initiates Rolling New Drug Application to U.s. Food and Drug Administration for PEDMARK™

PEDMARKTM is proposed to be indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic, solid tumors. ...
November 16, 2018 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Announces Scientific Symposium on Ototoxicity in Pediatric Cancer Patients at the 50th Congress of the International Society of Pediatric Oncology (SIOP) 2018 Meeting

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
November 13, 2018 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Provides Business Update and Announces Third Quarter 2018 Financial Results

Positive Opinion on the Pediatric Investigation Plan from EMA for PEDMARKTMTargeting US approval of PEDMARKTM in the second half of 2019Strong financial position with $24.5 million in cash and no debt...
September 26, 2018 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec to Present at Cantor Fitzgerald Global Healthcare Conference on October 1, 2018 in New York City

RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
August 13, 2018 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Provides Business Update and Announces Second Quarter 2018 Financial Results

Publication of PEDMARKTM SIOPEL 6 Clinical Data in The New England Journal of MedicineJoined Russell 3000 IndexStrong financial position with $25.6 million in cash and no debt RESEARCH TRIANGLE PARK,...
August 07, 2018 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Receives Positive Opinion on the Pediatric Investigation Plan From European Medicines Agency for PEDMARK(TM) and Confirmation of Eligibility for a Pediatric Use Marketing Authorization

RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Pediatric Committee...
June 21, 2018 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine

SIOPEL 6 met primary endpoint (p=0.002) 48% reduction in the incidence of hearing lossNo evidence of tumor protection RESEARCH TRIANGLE PARK, N.C., June 21, 2018 (GLOBE NEWSWIRE) -- Fennec...
June 11, 2018 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Set to Join Russell 3000 Index

RESEARCH TRIANGLE PARK, N.C., June 11, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
June 08, 2018 07:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 08, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy...